Guo Y - Search Results

1

Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.

Jia C, Kong D, Guo Y, Li L, Quan L. Jia C, et al. Among authors: guo y. Biochem Biophys Res Commun. 2018 Nov 2;505(3):720-725. doi: 10.1016/j.bbrc.2018.09.140. Epub 2018 Oct 3. Biochem Biophys Res Commun. 2018. PMID: 30292410

2

BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints.

Quan L, Lan X, Meng Y, Guo X, Guo Y, Zhao L, Chen X, Liu A. Quan L, et al. Among authors: guo y, guo x. Exp Hematol. 2018 Apr;60:47-56.e1. doi: 10.1016/j.exphem.2018.01.003. Epub 2018 Feb 3. Exp Hematol. 2018. PMID: 29353075 Free article.

3

Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma.

Chen Y, Quan L, Jia C, Guo Y, Wang X, Zhang Y, Jin Y, Liu A. Chen Y, et al. Among authors: guo y. J Proteome Res. 2021 May 7;20(5):2673-2686. doi: 10.1021/acs.jproteome.1c00007. Epub 2021 Mar 2. J Proteome Res. 2021. PMID: 33650432

4

HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.

Jia C, Guo Y, Chen Y, Wang X, Xu Q, Zhang Y, Quan L. Jia C, et al. Among authors: guo y. J Transl Med. 2022 Nov 18;20(1):537. doi: 10.1186/s12967-022-03750-8. J Transl Med. 2022. PMID: 36401285 Free PMC article.

5

Correction: HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.

Jia C, Guo Y, Chen Y, Wang X, Xu Q, Zhang Y, Quan L. Jia C, et al. Among authors: guo y. J Transl Med. 2023 Jan 30;21(1):58. doi: 10.1186/s12967-023-03904-2. J Transl Med. 2023. PMID: 36717915 Free PMC article. No abstract available.

6

Prognostic marker CD27 and its micro-environmental in multiple myeloma.

Wang X, Luo K, Xu Q, Chi L, Guo Y, Jia C, Quan L. Wang X, et al. Among authors: guo y. BMC Cancer. 2024 Mar 19;24(1):352. doi: 10.1186/s12885-024-11945-z. BMC Cancer. 2024. PMID: 38504180 Free PMC article.

7

Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram.

Guo Y, Lian J, Chen Y, Quan L, Guo X, Zhang J, Liu Z, Liu A. Guo Y, et al. Among authors: guo x. Hematology. 2025 Dec;30(1):2445395. doi: 10.1080/16078454.2024.2445395. Epub 2024 Dec 26. Hematology. 2025. PMID: 39722597 Free article.

8

Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.

Zhang J, Guo Y, Fang H, Guo X, Zhao L. Zhang J, et al. Among authors: guo y, guo x. Autoimmunity. 2023 Dec;56(1):2259126. doi: 10.1080/08916934.2023.2259126. Epub 2023 Sep 22. Autoimmunity. 2023. PMID: 37736847 Free article.

9

MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway.

Guo X, Zhang J, Zeng J, Guo Y, Zhao L. Guo X, et al. Among authors: guo y. PeerJ. 2023 Nov 6;11:e16388. doi: 10.7717/peerj.16388. eCollection 2023. PeerJ. 2023. PMID: 37953776 Free PMC article.

10

Establishment and evaluation of a nomogram for predicting the survival outcomes of patients with diffuse large B-cell lymphoma based on International Prognostic Index scores and clinical indicators.

Chen Y, Xu J, Meng J, Ding M, Guo Y, Fu D, Liu A. Chen Y, et al. Among authors: guo y. Ann Transl Med. 2023 Jan 31;11(2):71. doi: 10.21037/atm-22-6023. Ann Transl Med. 2023. PMID: 36819580 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44,989 results

Search Page

Filters